Login to Your Account

PharmAthene Raises $50M To Boost Anti-Bioterror Business

By Aaron Lorenzo

Wednesday, October 13, 2004
PharmAthene Inc. raised $50 million in its Series B round of financing. The Annapolis, Md.-based company, which is developing products to fight bioterrorism, plans to apply a portion of the funds to continue its development of ToxBlox, an inhibitor of anthrax toxin. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription